Literature DB >> 11886239

Dephosphorylation failure of tyrosine-phosphorylated STAT1 in IFN-stimulated Sendai virus C protein-expressing cells.

Sakura Saito1, Toshio Ogino, Naoko Miyajima, Atsushi Kato, Masayoshi Kohase.   

Abstract

Sendai virus C protein (SeV C) has been reported to counteract the antiviral activities of interferons (IFNs) by inhibiting the expression of IFN-stimulated gene products. In SeV C-expressing cells, formation of an active ISGF3 complex and translocation of STAT1 into the nucleus were not observed. STAT1 was continuously phosphorylated at tyrosine 701 by IFN signaling; however, its serine phosphorylation was suppressed. In addition, tyrosine-phosphorylated STAT1 grew to form abnormally huge complexes. These findings suggest that the counteraction of IFN in SeV C-expressing cells is caused by disordered phosphorylation and dephosphorylation of STAT1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886239     DOI: 10.1006/viro.2001.1250

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively.

Authors:  Megan L Shaw; Adolfo García-Sastre; Peter Palese; Christopher F Basler
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Importance of the anti-interferon capacity of Sendai virus C protein for pathogenicity in mice.

Authors:  Atsushi Kato; Katsuhiro Kiyotani; Toru Kubota; Tetsuya Yoshida; Masato Tashiro; Yoshiyuki Nagai
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

3.  The p127 subunit (DDB1) of the UV-DNA damage repair binding protein is essential for the targeted degradation of STAT1 by the V protein of the paramyxovirus simian virus 5.

Authors:  J Andrejeva; E Poole; D F Young; S Goodbourn; R E Randall
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 4.  Interferons and viruses: an evolutionary arms race of molecular interactions.

Authors:  Hans-Heinrich Hoffmann; William M Schneider; Charles M Rice
Journal:  Trends Immunol       Date:  2015-02-20       Impact factor: 16.687

5.  Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein.

Authors:  Achut G Malur; Santanu Chattopadhyay; Ratan K Maitra; Amiya K Banerjee
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling.

Authors:  Bin Gotoh; Kenji Takeuchi; Takayuki Komatsu; Junko Yokoo
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  The amino-terminal extensions of the longer Sendai virus C proteins modulate pY701-Stat1 and bulk Stat1 levels independently of interferon signaling.

Authors:  Dominique Garcin; Jean-Baptiste Marq; Stephen Goodbourn; Daniel Kolakofsky
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Characterization of the amino acid residues of sendai virus C protein that are critically involved in its interferon antagonism and RNA synthesis down-regulation.

Authors:  Atsushi Kato; Case Cortese-Grogan; Sue A Moyer; Fumihiro Sugahara; Takemasa Sakaguchi; Toru Kubota; Noriyuki Otsuki; Masayoshi Kohase; Masato Tashiro; Yoshiyuki Nagai
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Model-based analysis of interferon-beta induced signaling pathway.

Authors:  Jaroslaw Smieja; Mohammad Jamaluddin; Allan R Brasier; Marek Kimmel
Journal:  Bioinformatics       Date:  2008-08-19       Impact factor: 6.937

10.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.